What will Aytu win? Aytu is a “non-traditional” research company that acquires, licenses and markets late-stage therapeutic products and medicines in areas such as insomnia, sexual and reproductive health and severe cough. The company currently markets four products, namely the nasal angel NATESTO, which is the only nasally approved testosterone by the FDA for men suffering from primary hypogonadism, TUZISTRA® XR (Codiene Polistirex and Chlorphenine Polistirex), the only suspension for codine content for colds and coughs, ZOLPIMIST™ (Zolpidem-Tartrat) Oral Spray, the only FDA-authorized oral spray-zolpidem product to treat insomnia and THE MiOXSYS® SYSTEMan in vitro This acquisition will enable Aytu to enter the $40 billion consumer health market using a vast portfolio of innovators of more than 30 products covering areas with high therapeutic needs such as men`s health, diabetes, sexual well-being and respiratory well-being. This step helps Aytu expand its portfolio to non-prescription drugs that have a welcome supplement to its therapeutic prescription drugs that have seasonal demand as its range of cough suppressants. This would allow the company to achieve a wider distribution of turnover and a higher turnover due to the broadening of the product base. innovuspharma.com/content/pdf/innovus-pharma-fact-sheet.pdf As part of the proposed transaction between Aytu and Innovus, Aytu and Innovus will submit relevant documents to the Securities and Exchange Commission (SEC), including an Aytu registration statement on Form S-4 with a joint mandate from Aytu and Innovus, which also constitutes a prospectus of Aytu, and a joint final statement/prospectus will be sent to Aytu and Innovus shareholders. INVESTORS AND SECURITY HOLDERS OF AYTU AND INNOVUS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may receive free copies of the registration statement and joint proxy mandate (prospect) and other documents submitted by Aytu or Innovus to the SEC via the SEC-managed website under www.sec.gov. Copies of the documents submitted by Aytu to the SEC will be available free of charge on Aytu`s website under irdirect.net/AYTU under the title “SEC Submissions” or at (646) 755-7412 or [email protected] at Aytu. Copies of documents submitted by Innovus to the SEC will be available free of charge on the Innovus website, under innovuspharma.com/Investors/ under “SEC Submissions” or in contact with Innovus Investor Relations under [email protected] Our business development group is made up of industry experts who have experience in managing business relationships, evaluating every opportunity and implementing agreements that add value to our partners.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, amended, and Section 21E of the Securities Exchange Act of 1934 or the Exchange Act.